Elekta, IMPAC: Update on proposed merger
Elekta AB and IMPAC Medical Systems this week announced that, in connection with Elekta's proposed acquisition of IMPAC, both companies filed pre-merger notifications with the Department of Justice and the Federal Trade Commission on January 26. On February 25, the parties withdrew their pre-merger notifications and expect to refile the notifications on March 1, in order to provide additional time for the Department of Justice's review of the transaction, the companies said.
As a result of the new filing, the waiting period will expire on March 31, unless earlier terminated, or extended by a request for additional information and materials by the Antitrust Division or the Federal Trade Commission.
IMPAC also announced that it expects to file shortly its definitive proxy statement for a stockholders' meeting in late March or early April to approve the proposed acquisition.
As a result of the new filing, the waiting period will expire on March 31, unless earlier terminated, or extended by a request for additional information and materials by the Antitrust Division or the Federal Trade Commission.
IMPAC also announced that it expects to file shortly its definitive proxy statement for a stockholders' meeting in late March or early April to approve the proposed acquisition.